Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group.
Waszczuk-Gajda A et al. J Clin Apher. 2017 Sep 18. doi: 10.1002/jca.21584. [Epub ahead of print].
Autologous hematopoietic cell transplantation for multiple myelomapatients with renal insufficiency: a center for international blood and marrow transplant research analysis.
Mahindra A et al. Bone Marrow Transplant. 2017 Sep 18. doi: 10.1038/bmt.2017.198. [Epub ahead of print].
Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma.
Khouri J et al. Curr Opin Support Palliat Care. 2017 Sep 15. doi: 10.1097/SPC.0000000000000305. [Epub ahead of print].
In-patient versus out-patient autologous hematopoietic stem cell transplantation for multiple myeloma.
Shah N et al. Eur J Haematol. 2017 Sep 12. doi: 10.1111/ejh.12970. [Epub ahead of print].
Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.
Montefusco V et al. Bone Marrow Transplant. 2017 Sep 11. doi: 10.1038/bmt.2017.183. [Epub ahead of print].
Post-transplant Consolidation plus Lenalidomide Maintenance vs. Lenalidomide Maintenance Alone in Multiple Myeloma: A Systematic Review.
Al-Ani F et al. Eur J Haematol. 2017 Sep 8. doi: 10.1111/ejh.12961. [Epub ahead of print].
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Tzogani K et al. Oncologist. 2017 Sep 21. pii: theoncologist.2017-0184. doi: 10.1634/theoncologist.2017-0184. [Epub ahead of print].
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Kropff M et al. Ann Hematol. 2017 Sep 14. doi: 10.1007/s00277-017-3065-z. [Epub ahead of print].
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
Offidani M et al. Leuk Lymphoma. 2017 Sep 11:1-3. doi: 10.1080/10428194.2017.1372575. [Epub ahead of print].
Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma.
Isoda A et al. Leuk Lymphoma. 2017 Sep 6:1-2. doi: 10.1080/10428194.2017.1372579. [Epub ahead of print].
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Goldschmidt H et al. Leuk Lymphoma. 2017 Sep 22:1-11. doi: 10.1080/10428194.2017.1376743. [Epub ahead of print].
Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.
Ailawadhi S et al. Leukemia. 2017 Sep 1. doi: 10.1038/leu.2017.258. [Epub ahead of print].